VISTN Vistin Pharma ASA

Vistin Pharma enters into a long-term renewable energy supply agreement with Statkraft

Vistin Pharma enters into a long-term renewable energy supply agreement with Statkraft

Oslo, Norway, 9 December 2022

Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) announces that it has entered into a long-term industrial energy agreement with Statkraft, the leading Norwegian energy supplier. The agreement will secure a significant part of Vistin’s electricity demand on competitive terms until 2032. The agreement includes Guarantees of Origin as certification of the renewable energy supply, and starts 1.1.2023.

2022 has been very challenging for Vistin and the Norwegian industry, when it comes to electricity costs, with extreme volatility and record high electricity prices in the NO2 area where Vistin’s fully automated production plant is located.

- This agreement will give Vistin Pharma stable electricity supply at predictable and competitive prices. The agreement helps to secure our competitiveness in the global Metformin market. We are happy that Statkraft by this agreement contributes to the future development of Vistin and thereby allows the company to continue focusing on its growth strategy, says Kjell-Erik Nordby, CEO in Vistin Pharma.

- We are very pleased to conclude another renewable energy contract with the Norwegian industry which confirms that Statkraft offers relevant solutions at competitive terms, says Frode Berntsen, Head of Industry Nordics & Baltics at Statkraft.  

About Vistin Pharma |

Vistin Pharma is a Norwegian pharmaceutical company producing Metformin Hydrochloride (API). The Metformin is also available as Direct Compressible lubricated granules. As a solely dedicated European Metformin producer, Vistin Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin Pharma is headquartered in Oslo, Norway, and has highly qualified employees and a dedicated manufacturing facility in Kragerø.

About Statkraft |

Statkraft is a leading company in hydropower internationally and Europe's largest generator of renewable energy. The Group produces hydropower, wind power, solar power, gas-fired power and supplies district heating. Statkraft is a global company in energy market operations Statkraft has 4,800 employees in 20 countries.

*****

For further information, please contact:

Alexander Karlsen

CFO

 36 21

 



EN
09/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vistin Pharma ASA

 PRESS RELEASE

Vistin Pharma ASA: Mandatory notification of trade

Vistin Pharma ASA: Mandatory notification of trade Magnus Tolleshaug, Chief Executive Officer in Vistin Pharma ASA, and a primary insider, has on 20'th of February 2026 purchased 30.000 shares in Vistin Pharma ASA at an average price of NOK 21,10 per share. Following this purchase Magnus Tolleshaug holds 105.000 shares in Vistin Pharma ASA.   Attachment

 PRESS RELEASE

Vistin Pharma ASA (VISTN): Key information relating to the proposed ca...

Vistin Pharma ASA (VISTN): Key information relating to the proposed cash dividend The Board of Directors will propose for the AGM to get a power of attorney to pay-out an ordinary cash dividend of up to NOK 1.50 per share, to be paid partly with NOK 1 in May and up to NOK 0.50 in November, for the accounting year of 2025. The formal decision regarding the dividend will be made on the company's Annual General Meeting, which will be held on 20 May 2026. Dividend amount (per share): NOK 1 Declared currency: NOK Last day including right: 21 May 2026 Ex-date: 22 May 2026 Record date: 26 May...

 PRESS RELEASE

Vistin Pharma ASA: Fourth quarter and preliminary 2025 financial resul...

Vistin Pharma ASA: Fourth quarter and preliminary 2025 financial results Oslo, Norway, 12th of February 2026 Vistin Pharma ASA (VISTN) today announces the financial results for the fourth quarter and preliminary results of 2025. Solid last quarter of 2025 signs-off a record year for Vistin Pharma with all-time high revenue and EBITDA. Revenue in the fourth quarter ended at MNOK 111 compared to MNOK 114 in Q4 2024. Record high sales volume in quarter (+9%), offset by lower global metformin prices compared to same quarter last year. 2025 full year revenue ended at all-time high MNOK 452 com...

 PRESS RELEASE

Vistin Pharma ASA (VISTN): Invitation to Q4 2025 conference call

Vistin Pharma ASA (VISTN): Invitation to Q4 2025 conference call Oslo, Norway, 5 February 2026 Vistin Pharma ASA will release its fourth quarter and preliminary 2025 results on Thursday 12th of February 2025. Vistin Pharma will host a conference call for all shareholders and interested parties on the same day at 08:30 CET. There will be a Q&A session following the management discussion. The conference call will be held in English. The fourth quarter conference call will be available via web and audio through the following access points: Webcast: Telephone conference (online registrati...

 PRESS RELEASE

Vistin Pharma ASA: Third quarter and YTD 2025 financial results

Vistin Pharma ASA: Third quarter and YTD 2025 financial results Vistin Pharma ASA: Third quarter and YTD 2025 financial results Oslo, Norway, 31st of October 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2025. Revenue in the third quarter ended at MNOK 109 compared to MNOK 106 in Q3 2024. The increase in revenue was driven by 10% higher sales volume. Revenue YTD 2025 ended at MNOK 342 compared to MNOK 316 YTD last year, an increase of 8% Third quarter EBITDA ended at MNOK 28 compared to MNOK 29 in Q3 2024. EBITDA of MNOK 28 positively affe...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch